Healthcare Equipment and Supplies
Company Overview of Provista Diagnostics, Inc.
Provista Diagnostics, Inc. is a molecular diagnostics company that focuses on developing and commercializing blood-based diagnostic, prognostic, and monitoring tests to address the unmet needs in women's cancers. The company develops a pipeline of blood-based molecular diagnostic tests to address the unmet needs in breast, ovarian, endometrial, and human papillomavirus (HPV) associated cancers. Its products include Videssa Breast, a biomarker panel along with patient data and statistical modeling to improve standard of care in women with suspicious breast lesions; Videssa Ovarian, a blood-based biomarker assay to aid in the earlier diagnosis of ovarian cancer and monitor for recurrence; Vide...
160 Varick Street
New York, NY 10013
Founded in 2007
Key Executives for Provista Diagnostics, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2015.
Provista Diagnostics, Inc. Key Developments
Provista Diagnostics, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 01:20 PM
Oct 31 15
Provista Diagnostics, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 01:20 PM. Venue: Westin Grand Central, New York, New York, United States. Speakers: David E. Reese, Chief Executive Officer and President.
Provista Diagnostics, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 08:00 AM
Oct 7 15
Provista Diagnostics, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 08:00 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.
Provista Diagnostics, Inc. Completes Enrollment of the 2nd Cohort of its 002 Prospective, Multi-Center, Randomized Trial Utilizing the Provista Biomarker Assay to Aid in the Detection of Breast Cancer
Aug 13 15
Provista Diagnostics, Inc. announced that they completed enrollment of the 2nd cohort of a prospective study of their protein-based biomarker blood test to aid in detection of breast cancer. Provista's 2nd cohort of its 002 study enrolled a total of 509 women that will be monitored for 6 and 12 months for clinical outcomes. Together, cohorts 1 and 2 of Provista's 002 study has recruited a total of 1,020 patients. The study is a prospective, multi-center, randomized trial that seeks to validate Provista's blood-based biomarker panel assay in conjunction with imaging to differentiate benign breast lesions from invasive cancers. This multi-center trial is a follow-up to Provista's 001 trial that recruited 351 women under the age of 50 with suspicious lesions thus, bringing Provista's collective prospective clinical trial enrollment to 1,371 patients to date. To evaluate whether Provista's blood test could aid in the detection of breast cancer, patients were prospectively enrolled in a randomized trial at 12 breast cancer centers across the United States. A small quantity of blood was drawn from patients to analyze several protein biomarkers and their expression patterns were evaluated by a proprietary algorithm to yield a unique protein signature. The goal of the study is to determine whether a collection of biomarkers identified by Provista's test can differentiate malignant from benign tumors.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 23, 2015
February 17, 2015